Benzinga | Nov 10, 2021 06:08PM EST

Regulus Therapeutics Q3 EPS $(0.10) Misses $(0.08) Estimate

Regulus Therapeutics (NASDAQ:RGLS) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.08) by 25 percent. This is a 150 percent decrease over losses of $(0.04) per share from the same period last year.